drugset

drugset / Trial / NCT00730652

Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma

NCT00730652 ↗

Phase 1 Withdrawn 34 enrolled Bristol-Myers Squibb

NaSingle-groupOpen-labelTreatment

Summary

To determine if MDX-1411 is safe for the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.

Timeline

Start: 2009-05
Primary completion: 2012-12
Completion: 2013-03

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MDX-1411	Monoclonal antibody	—	Intravenous

Indications